NanoViricides Reports at NanoBiotech 2006 Conference: AviFluCide-I(TM) and FluCide-I(TM)Best Drugs against H5N1 and Common Influenzas, Respectively
WEST HAVEN, Conn., Nov 27, 2006 (BUSINESS WIRE) -- NanoViricides, Inc., (Pink Sheets: NNVC)
Dr. Anil Diwan, Company President and Chairman, provided a synthesis of the results so far obtained against common influenza (H1N1) animal studies and avian flu (H5N1) cell culture studies at the NanoBiotech 2006 Conference in Boston on November 17th.
"We can extrapolate that AviFluCide could be between 40 times (4,000%) to 200 times (20,000%) superior to Tamiflu in H5N1 field events," said Dr. Diwan, explaining this with scientific data, "We know that AviFluCide-I was almost 4 times superior to FluCide against H5N1, and that FluCide was almost 10 times (1000%) superior to Oseltamivir (Tamiflu(R) Roche) in animal studies. Further, Tamiflu efficacy against H5N1 may be as low as 1/10th its efficacy against common influenza, as suggested by several international studies in mice as well as scant clinical data from human treatment."
"Our upcoming H5N1 animal studies in Vietnam should provide significant important data. Often, the simple mathematical relationships are not upheld in animal studies because the biological systems are very complex," said Dr. Krishna Menon, Chief Regulatory Officer, who conducted the animal studies. He further added, "Nevertheless, it is quite clear that these nanoviricides appear to be currently the best drugs available against influenzas including avian flu."
nanoviricides.com |
